Villa-Forte Alexandra, Mandell Brian F
Center for Vasculitis Care and Research, Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, Ohio, USA.
Rev Esp Cardiol. 2011 Sep;64(9):809-17. doi: 10.1016/j.recesp.2011.05.009. Epub 2011 Jul 16.
Cardiovascular disease is a common and under-recognized problem in patients with systemic rheumatic conditions. Patients may present with disease associated heart involvement at the time of diagnosis or later in the course of the illness. The manifestations vary by disease, and all structures in the heart can be affected and may result in significant morbidity and mortality. Manifestations of cardiac disease in these patients range from subclinical to severe and may require aggressive immunosuppressive therapy. Early recognition is important for prompt institution of appropriate therapy. Treatment of disease associated cardiac involvement is based on severity of disease with more severe manifestations often requiring a combination of corticosteroid and cytotoxic agent. Premature atherosclerosis has been increasingly recognized in patients with systemic lupus erythematosus and rheumatoid arthritis and may result in premature coronary death when compared to the general population. Aggressive control of systemic inflammation in these diseases may result in a reduction in the risk of ischemic heart disease. Although aggressive treatment of the primary rheumatic disease has been associated with an improvement in mortality rates, specific guidelines for prevention of ischemic heart disease in this group of patients have not been formulated and recommendations at this time include aggressive control and monitoring of traditional risk factors.
心血管疾病在患有全身性风湿性疾病的患者中是一个常见但未得到充分认识的问题。患者可能在诊断时或疾病过程后期出现与疾病相关的心脏受累情况。其表现因疾病而异,心脏的所有结构都可能受到影响,并可能导致显著的发病率和死亡率。这些患者的心脏疾病表现从亚临床到严重不等,可能需要积极的免疫抑制治疗。早期识别对于及时开始适当治疗很重要。与疾病相关的心脏受累的治疗基于疾病的严重程度,更严重的表现通常需要联合使用皮质类固醇和细胞毒性药物。与普通人群相比,系统性红斑狼疮和类风湿关节炎患者中过早动脉粥样硬化的情况越来越受到认可,这可能导致过早的冠状动脉死亡。积极控制这些疾病中的全身炎症可能会降低缺血性心脏病的风险。尽管对原发性风湿性疾病的积极治疗与死亡率的改善有关,但目前尚未制定针对这组患者预防缺血性心脏病的具体指南,目前的建议包括积极控制和监测传统危险因素。